

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of Cayman Islands with limited liability)

(Stock Code: 6833)

APPOINTMENT OF INDEPENDENT FORENSIC ACCOUNTANT



Financial Advisor

Diligent Capital Limited

Reference is made to the announcements of the Company dated 26 September 2022, 30 September 2022 and 24 October 2022 in relation to the Incident (the “**Announcements**”). Unless the context requires otherwise, the capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The board of directors of the Company (the “**Board**”) announces that on 21 December 2022, the Independent Committee appointed Grant Thornton Advisory Services Limited, an independent forensic accountant, to conduct an independent forensic investigation into the Incident (the “**Independent Investigation**”) and produce a report on the findings of the Independent Investigation to be presented to the Independent Committee. The Company will publish further announcement(s) on the material development and progress in relation to the Independent Investigation as and when appropriate.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 4 January 2023

As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.